Premiere Publications from
The Triological Society

Read all three of our prestigious publications, each offering high-quality content to keep you informed with the latest developments in the field.

THE LARYNGOSCOPE
FOUNDED IN 1896

Editor-in-Chief: Samuel H. Selesnick, MD, FACS
The leading source for information in head and neck disorders.
Laryngoscope.com

LARYNGOSCOPE
INVESTIGATIVE OTOLARYNGOLOGY

Editor-in-Chief: D. Bradley Welling, MD, PhD, FACS
Rapid dissemination of the science and practice of otolaryngology-head and neck surgery.
InvestigativeOto.com

ENT TODAY
A PUBLICATION OF THE TRILOGICAL SOCIETY

Editor-in-Chief: Alexander Chiu, MD
Must-have timely information that Otolaryngologist-head and neck surgeons can use in daily practice.
Enttoday.org

WILEY
Dear editor,

We read with interest the article by Harb et al. suggesting surgery should be offered to all children with cervicofacial nontuberculous mycobacterial (NTM) lymphadenitis. This conclusion is based on only four cited studies. As summarized in our recent meta-analysis, many other studies have investigated the three main management options—complete excision, anti-mycobacterial antibiotics, and no intervention (“watchful waiting”).

Although complete excision had the highest cure rate in our meta-analysis, this is not invariably the best option as suggested by the authors. Management decisions regarding NTM lymphadenitis require an interdisciplinary, individualized approach considering several factors, including disease stage (excision is more likely to be successful in early stages), local surgical expertise, proximity of the lymph node to the facial nerve (complete excision is associated with a 10% risk of facial nerve palsy, permanent in 2%), and parental attitude to an invasive procedure compared with prolonged time to resolution with conservative options.

As evidence for “no intervention,” the authors summarize results from only two studies, both of which showed a 100% cure rate. However, there are several others, including a recent study from Finland, that have reported lower cure rates. Importantly, 30% of asymptomatic children respond to Mycobacterium avium sensitkin skin testing (the predominant pathogen in NTM lymphadenitis), suggesting subclinical and mild disease that is self-limiting is not uncommon.

Regarding anti-mycobacterial antibiotics, Harb et al. mention only one randomized controlled trial that had substantial flaws, as detailed elsewhere. Although, in our meta-analysis the adjusted mean cure rate with anti-mycobacterial treatment was 73%, the risk of bias is substantial as children with more advanced disease are more likely to receive anti-mycobacterial antibiotics. Furthermore, there was considerable heterogeneity in antibiotic choice and treatment duration across different studies.

In our meta-analysis, adverse events were reported in 68% of children who received anti-mycobacterial treatment, but these were almost universally mild and transient, resulting in management changes in only 3%. Although the authors state that non-surgical options leave patients prone to fistula formation, in our meta-analysis only 4% of the children treated with anti-mycobacterial antibiotics developed a fistula.

In summary, the existing evidence to guide the management of NTM lymphadenitis is limited, and no randomized controlled trial has compared the three main options. Until such data become available, treatment decisions should be individualized taking into account the above-mentioned factors. Importantly, while complete excision may have the highest cure rate, it also carries the highest risk of serious adverse events.

PETRA ZIMMERMANN, MD, PhD
Department of Paediatrics, Fribourg Hospital HFR and Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Infectious Diseases Research Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia

NICOLE RITZ, MD, PhD
Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
Infectious Diseases Unit Basel, University of Basel Children’s Hospital, Basel, Switzerland
Mycobacterial Research Group, Department of Clinical Research, University of Basel, Basel, Switzerland

NIGEL CURTIS, FRCPCH, PhD
Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
Infectious Diseases Research Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia
Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia

MARC TEBBUEGGE, MD, PhD
Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
Department of Paediatric Infectious Diseases & Immunology, Evelina London Children’s Hospital, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Department of Infection, Immunity & Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom

The authors have no funding or conflicts of interest to declare. Send correspondence to Petra Zimmermann, MD, PhD, Faculty of Science and Medicine, University of Fribourg, Route des Arsenaux 41, 1700 Fribourg, Switzerland. E-mail: petra.zimmermann@unifr.ch

DOI: 10.1002/lary.28608